Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18638701 | 1.00 | NR1I2 (0.45) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL19560021 | 0.98 | ALDH1A1 (0.45) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL18635879 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL9227674 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL3443068 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL18559449 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL9227794 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL18559615 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL19513573 | 0.98 | NR1I2 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA | |
| SCHEMBL18559574 | 0.96 | ALDH1A1 (0.46) | NR1I2ALDH1A1MAPTPOLBNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905252-B2 | Compounds | INFLAZOME LIMITED (IE) | 2024-02-20 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20210347737-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-11-11 | — | — | US | disclosed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905252-B2 | Compounds | NLRP3, NOD1, PYCARD | NR1I2 938/4885ALDH1A1 559/4885MAPT 1345/4885 |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | AZI2, FURIN, ACE2 | NR1I2 647/4885ALDH1A1 1328/4885MAPT 4568/4885 |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | AZI2, FURIN, ACE2 | NR1I2 647/4885ALDH1A1 1328/4885MAPT 4568/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NR1I2 1237/4885ALDH1A1 2123/4885MAPT 2169/4885 |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | NR1I2 2341/4885ALDH1A1 3413/4885MAPT 3547/4885 |
| US-20210347737-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, NOD2 | NR1I2 753/4885ALDH1A1 1032/4885MAPT 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.